Updated mini-review of the chemistry, pharmacology and validated assays for U.S. FDA approved COVID-19 therapeutic agents

Abstract

The fish market in Wuhan, China was the epicenter of Covid-19 pandemic, brought about by SARS-Co-V-2. The latter has radiated worldwide, resulting in significant economic and social disruption “Covid Crisis”. Although numerous drugs have been indicated for treating the viral infection and/or its symptoms, U.S. FDA has granted approvals for only three therapeutic agents; Remdesivir, Baricitinib and Monoclonal Antibodies (Bamlanivimab/Etesevimab, Casirivimab/Imdevimab). This review assigns the approved drug entities with respect to their chemical and pharmacological aspects as well as their reported analyses in marketed formulations and biological matrices. Furthermore, it offers a comparative study between the cited analytical methodologies for each drug separately. A comprehensive, detailed, yet an instant message of Coronavirus authorized cure is delivered throughout the presented review.

Keywords

• covid-19
• remdesivir
• baricitinib
• monoclonal antibodies